It is that really happened, which was proclaimed researchers He Jiankui from China on Monday, surprisingly, and without scientifically-tested publication: The first baby, whose genetic material has been altered before birth by using a genetic engineering method called Crispr/Cas9, have been born. On Wednesday He said at a conference in Hong Kong, moreover, that a further woman with a of him with this Genschere modified Embryo was pregnant. The scientists must do more to help people with diseases, said He. Researchers from all over the world criticized the scientists violently for this ethical transgression.
Emmanuelle Charpentier, one of the Discoverers of the Crispr/Cas9 mechanism behind the method, has been critical. She was “very concerned about this message” you’ve met, surprisingly, said the microbiologist, in a Statement, the is TIME ONLINE. “Although we have so far seen no scientific evidence, for example in the Form of a published professional article in a magazine, you would have to go through the Peer-Review process, He Jiankui exceeded clearly a red line,” informed the Director at the Max-Planck-Institute for infection biology in Berlin. This alone is exceeded by the fact that He had ignored the concerns of the international community of researchers, with a view to the safety of such technology, when applied in the germline of the person.
the other major developers of the Genschere have distanced themselves from the experiments on embryos. These include Charpentier’s former colleague, the U.S. researcher Jennifer Doudna, Feng Zhang, is with the two female Explorers is currently in a patent dispute over the rights to the method.
Emmanuelle Charpentier, Emmanuelle Charpentier
The microbiologist was born in 1968 in Juvisy-sur-Orge, South of Paris. Charpentier studied biology and genetics at the Université Pierre et Marie Curie (UPMC) and did her PhD at the Pasteur Institute.
After stops in Vienna, in the Swedish city of Umeå as well as at the Helmholtz centre for infection research in Braunschweig, the Frenchwoman 2015 was appointed as a Director at the Max-Planck-Institute for infection biology in Berlin. Currently Charpentier builds her own Institute, the Max-Planck-research centre for the science of the Pathogens. She has received numerous awards for her basic research on Crispr/Cas9, a technology that the genome of the target that can be used to change.
